TMC Life Sciences Berhad

KLSE:TMCLIFE Stock Report

Market Cap: RM 862.2m

TMC Life Sciences Berhad Past Earnings Performance

Past criteria checks 2/6

TMC Life Sciences Berhad has been growing earnings at an average annual rate of 21.2%, while the Healthcare industry saw earnings growing at 21.8% annually. Revenues have been growing at an average rate of 13.9% per year. TMC Life Sciences Berhad's return on equity is 3.2%, and it has net margins of 8.5%.

Key information

21.2%

Earnings growth rate

21.1%

EPS growth rate

Healthcare Industry Growth31.5%
Revenue growth rate13.9%
Return on equity3.2%
Net Margin8.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

TMC Life Sciences Berhad (KLSE:TMCLIFE) Seems To Use Debt Quite Sensibly

Feb 14
TMC Life Sciences Berhad (KLSE:TMCLIFE) Seems To Use Debt Quite Sensibly

We Think TMC Life Sciences Berhad (KLSE:TMCLIFE) Can Stay On Top Of Its Debt

Sep 29
We Think TMC Life Sciences Berhad (KLSE:TMCLIFE) Can Stay On Top Of Its Debt

Investors Met With Slowing Returns on Capital At TMC Life Sciences Berhad (KLSE:TMCLIFE)

Aug 26
Investors Met With Slowing Returns on Capital At TMC Life Sciences Berhad (KLSE:TMCLIFE)

TMC Life Sciences Berhad (KLSE:TMCLIFE) Shareholders Will Want The ROCE Trajectory To Continue

May 26
TMC Life Sciences Berhad (KLSE:TMCLIFE) Shareholders Will Want The ROCE Trajectory To Continue

TMC Life Sciences Berhad's (KLSE:TMCLIFE) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Feb 09
TMC Life Sciences Berhad's (KLSE:TMCLIFE) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Returns On Capital - An Important Metric For TMC Life Sciences Berhad (KLSE:TMCLIFE)

Jan 13
Returns On Capital - An Important Metric For TMC Life Sciences Berhad (KLSE:TMCLIFE)

Revenue & Expenses Breakdown

How TMC Life Sciences Berhad makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KLSE:TMCLIFE Revenue, expenses and earnings (MYR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243362800
30 Jun 243464100
31 Mar 243575300
31 Dec 233535700
30 Sep 233324800
30 Jun 233123900
31 Mar 232984900
31 Dec 222774200
30 Sep 222634400
30 Jun 222444100
31 Mar 222262200
31 Dec 212131800
30 Sep 212031700
30 Jun 212012000
30 Jun 201841600
31 May 201901000
29 Feb 202062200
30 Nov 192002200
31 Aug 191952100
31 May 1918733880
28 Feb 1918030880
30 Nov 1817429880
31 Aug 181692800
31 May 1816528280
28 Feb 1816128460
30 Nov 1715728620
31 Aug 1715226790
31 May 1714621790
28 Feb 1714020770
30 Nov 1613619760
31 Aug 1613118740
29 Feb 1612113690
30 Nov 1511613670
31 Aug 1510710550
31 May 1510310610
28 Feb 15989570
30 Nov 14947540
31 Aug 14918520
31 May 14866510
28 Feb 14825500

Quality Earnings: TMCLIFE has high quality earnings.

Growing Profit Margin: TMCLIFE's current net profit margins (8.5%) are lower than last year (14.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TMCLIFE's earnings have grown significantly by 21.2% per year over the past 5 years.

Accelerating Growth: TMCLIFE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: TMCLIFE had negative earnings growth (-40.9%) over the past year, making it difficult to compare to the Healthcare industry average (2.4%).

Return on Equity

High ROE: TMCLIFE's Return on Equity (3.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:54
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TMC Life Sciences Berhad is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shin KaoOSK-DMG